Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7246402

Reference Type

Journal Article

Title

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Author(s)

Jernerén, F; Cederholm, T; Refsum, H; Smith, AD; Turner, C; Palmblad, J; Eriksdotter, M; Hjorth, E; Faxen-Irving, G; Wahlund, LO; Schultzberg, M; Basun, H; Freund-Levi, Y; ,

Year

2019

Is Peer Reviewed?

Yes

Journal

Journal of Alzheimer's Disease
ISSN: 1387-2877
EISSN: 1875-8908

Publisher

IOS PRESS

Location

AMSTERDAM

Page Numbers

189-197

Language

English

PMID

30958356

DOI

10.3233/JAD-181148

Web of Science Id

WOS:000467519100017

Abstract

Trials of supplementation with omega-3 fatty acids (ω3-FAs) in patients with mild cognitive impairment or Alzheimer's disease (AD) have produced inconsistent effects on cognitive decline. There is evidence of an interaction between B vitamin status and ω3-FAs in relation to brain atrophy and cognitive decline.